May, 2022. The abstract of our study of using DeepRx COLOXIS system to guide regimen selection for adjuvant therapy of colon cancer is published in ASCO 2022. The significance of this work is two-fold: First, if applied in practice, the system potentially can improve clinical outcomes of over a million colorectal cancer patients worldwide. Second, this study provides the first evidence that AI methods can be used to predict efficacy of chemotherapy and biological drugs in a real clinical setting. Since chemo drugs remain the backbone of contemporary oncology, this study opens the new direction of developing more AI models to guide application of more chemotherapy agents to treat different cancers, which will benefit millions of patients.